See all eligibility criteria
See protocol details
RATIONALE: Evaluating specific proteins in the blood may be an effective and noninvasive procedure to help doctors determine if a patient has early non-small cell lung cancer. PURPOSE: This clinical trial is studying proteomic profiling to see how well it works in diagnosing non-small cell lung cancer in patients who are undergoing resection for suspicious (abnormal) stage I lung lesions. OBJECTIVES: Primary * Determine, prospectively, whether serum proteomic profiling can predict the presence of primary non-small cell lung cancer in patients with clinically suspicious stage I lung lesions who are undergoing lung resection. Secondary * Correlate the serum proteomic profile with pathologic nodal status and histopathologic features of primary lung cancer in these patients. * Correlate the initial and follow-up serum proteomic profile with overall and cancer-specific survival of these patients. * Correlate changes in the proteomic profile (preoperative to postoperative) with overall and cancer-specific survival of these patients. Tertiary * Determine whether novel molecular strategies can predict the presence of lung cancer and/or the biologic behavior of an individual cancer in these patients.
Show More Criteria
is designated in this study